Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Azithromycin package © www.doctor-4-u.co.uk/ via Flickr

Conducted by the Oxford Clinical Trials Research Unit (OCTRU) and the University of Oxford’s Nuffield Department of Medicine, the ATOMIC2 trial investigated if the common antibiotic azithromycin could prevent patients with mild-moderate COVID-19 from getting worse. 

Azithromycin is a safe, inexpensive and commonly prescribed antibiotic that is available worldwide. It has a wide range of antibacterial, anti-inflammatory and antiviral properties, but there were no strong data proving whether it was effective in COVID-19. 

Supported by the NIHR Oxford Biomedical Research Centre (BRC)the ATOMIC2 trial, randomised 298 participants to either azithromycin (500 mg once daily for 14 days) or to standard treatment without azithromycin. The primary endpoint – death or hospitalisation from any cause – was not significantly different between the two groups; neither were rates of respiratory failure, progression to pneumonia, all-cause mortality, and adverse events, including serious cardiovascular events. 

 

Dr Timothy Hinks, Chief Investigator of the ATOMIC2 trial and an Oxford BRC Senior Research Fellow, said: “Azithromycin is a very valuable antibiotic used the world over for treating a wide range of serious infections, and remains an essential tool for any healthcare system. Its overuse, where not clearly proven to be of benefit, carries a very strong risk of driving the development of multi-resistant bacteria. 

“The ATOMIC2 trial adds to the now very strong set of evidence that azithromycin is not effective in COVID-19 and it is essential it should be preserved for diseases where it is really needed.” 

As well as the Oxford BRC, the trial was supported by Pfizer and from philanthropic donations provided via the University of Oxford COVID-19 Research Response Fund. 

Similar stories

Furniss Group paper wins journal award

Editors at the Journal of Hand Surgery have recognised the Furniss Group with an award for the best paper published in the Journal in 2022. The Editor’s Award recognises research with scientific importance, outstanding study stringency, and a high academic standard.

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

ORUK Early Career Research Fellowship awarded to NDORMS researcher

Congratulations to Jack Tu who has been awarded an Orthopaedic Research UK Early Career Research Fellowship to explore the cause of knee pain after total knee replacement.

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Unhelpful thoughts about fracture symptoms hinder recovery

The importance of mindsets and feelings about fracture symptoms have been shown to be a key factor in recovery of musculoskeletal conditions.